Is eribulin treatment prognostic factor in patients with metastatic breast cancer treated with this drug? Retrospective analysis of a multicentre study

Basit Öğe Kaydı
dc.contributor.authorOruc, Zeynep
dc.contributor.authorKaplan, Muhammet Ali
dc.contributor.authorGeredeli, Caglayan
dc.contributor.authorSari, Nilgun Yildirim
dc.contributor.authorOzaslan, Ersin
dc.contributor.authorAytekin, Aydin
dc.contributor.authorElkiran, Emin Tamer
dc.date.accessioned2024-04-24T17:37:35Z
dc.date.available2024-04-24T17:37:35Z
dc.date.issued2020
dc.departmentDicle Üniversitesien_US
dc.description.abstractPurpose: This study aimed to analyze prognostic factors for survival and the reliability and the effectiveness of eribulin therapy in metastatic breast cancer (MBC) patients. Methods: A total of 80 patients treated with eribulin in 12 medical oncology centers in Turkey between 2013-2017 were retrospectively evaluated. Sixteen potential prognostic variables were assessed for analysis. Results: The patients had received a median of 5 prior chemotherapy regimens and a median of 3 eribulin cycles for MBC. Median progression free survival (PFS) was 5.5 months (95% CI: 4.1-7.8) and median overall survival (OS) was 11 months (95 % CI: 6-15). Multivariate analysis showed that eribulin treatment line was shown to have independent prognostic significance for PFS. PFS difference was demostrated in patients who received 3 chemotherapy lines for advanced disease compared to those who had more than 3 chemotherapy lines [median PFS; 3 lines: 8.6 months (6.2-11) and >3 lines: 4.6 months (3.7-16) p=0.00]. The clinical benefit rate (CBR) was 52.5 and 35% in patients treated with three lines and with >3 previous chemotherapeutic regimens. Most common toxicities were neutropenia (62.5%), fatigue (52.5%), alopecia (50%) and nausea (37.5%). Conclusions: Eribulin treatment line was identified as indepedent prognostic factor for PFS in MBC patients.en_US
dc.identifier.endpage647en_US
dc.identifier.issn1107-0625
dc.identifier.issn2241-6293
dc.identifier.issue2en_US
dc.identifier.pmid32521847
dc.identifier.scopus2-s2.0-85084634447
dc.identifier.scopusqualityQ3
dc.identifier.startpage641en_US
dc.identifier.urihttps://hdl.handle.net/11468/21045
dc.identifier.volume25en_US
dc.identifier.wosWOS:000549860000010
dc.identifier.wosqualityQ4
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoenen_US
dc.publisherImprimatur Publicationsen_US
dc.relation.ispartofJournal of Buon
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectMetastatic Breast Canceren_US
dc.subjectEribulinen_US
dc.subjectChemotherapyen_US
dc.subjectPrognostic Factorsen_US
dc.subjectBreast Canceren_US
dc.titleIs eribulin treatment prognostic factor in patients with metastatic breast cancer treated with this drug? Retrospective analysis of a multicentre studyen_US
dc.titleIs eribulin treatment prognostic factor in patients with metastatic breast cancer treated with this drug? Retrospective analysis of a multicentre study
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu